Pudong-produced robot completes first lung surgery
A surgical robot developed by Shanghai MicroPort Medical (Group) Co for the treatment of COVID-19 conducts its first human trial at the Shanghai Chest Hospital on April 24. [Photo/WeChat account: pdnews]
A surgical robot developed by Shanghai MicroPort Medical (Group) Co for the treatment of COVID-19 completed its first broncho-alveolar lavage surgery on April 24 at the Shanghai Chest Hospital.
The surgery was conducted on a 55-year-old male patient who was suspected of suffering a pulmonary infection. It took just 30 minutes to complete.
It is the world's first bronchus surgery robotic system designed for the treatment of COVID-19 and is capable of carrying out lavage surgery and tracheal incubation. It allows medical workers to conduct surgeries remotely from an isolated room, protecting them from infection.
A surgical robot developed by Shanghai MicroPort Medical (Group) Co for the treatment of COVID-19 [Photo/WeChat account: pdnews]
The system has passed assembly tests, animal experiments, and even its first human trial.
According to a spokesperson for MicroPort, although the robot was designed for COVID-19 treatment, it can also be used in the treatment of other highly infectious respiratory diseases such as tuberculosis.
The robot's research and development team is committed to developing technology for minimally invasive surgical robots and commercializing its products.
The DFVion3D electronic laparoscope and the Toumai endoscopic surgery robot are currently undergoing a national vetting process for innovative medical equipment.